Stay updated with breaking news from Roivant Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Roivant's shares gained 4% in afternoon trading, while its subsidiary Arbutus rose more than 17%. In a so-called "claim construction order", U.S. District Judge Mitchell Goldberg interpreted parts of the patents in ways that strengthened Arbutus' case, rejecting Moderna's proposed definitions. The order is relevant in determining whether Moderna's vaccines are covered by Arbutus' patented technology.
Roivant Sciences said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study. In the study testing...
Roivant Sciences' experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study, sending the biotech firm's...
Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) gapped up prior to trading on Wednesday . The stock had previously closed at $10.08, but opened at $10.72. Roivant Sciences shares last traded at $10.75, with a volume of 4,818,374 shares changing hands. Analysts Set New Price Targets A number of equities research analysts have recently […]